Read-Gene (WAR:RDG) Total Liabilities: zł10.24 Mil (As of Mar. 2026)

Author:

Vera Yuan

Director of Data and Quant Analytics at GuruFocus

Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.

View Profile →

Reviewed by:

Charlie Tian

Founder & CEO of GuruFocus

Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

View Profile →

Valuation Modestly Undervalued

1 Warning Sign

View Full Analysis

What is Read-Gene Total Liabilities?

Read-Gene WAR:RDG 80 Total Liabilities is zł10.24 Mil as of Mar. 2026. GuruFocus rates WAR:RDG with a GF Score™ of 80/100 and a GF Value™ of zł6.37 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Read-Gene's Total Liabilities for the quarter that ended in Mar. 2026 was zł10.24 Mil.

Read-Gene's quarterly Total Liabilities increased from Sep. 2025 (zł10.53 Mil) to Dec. 2025 (zł12.14 Mil) but then declined from Dec. 2025 (zł12.14 Mil) to Mar. 2026 (zł10.24 Mil).

Read-Gene's annual Total Liabilities increased from Dec. 2023 (zł10.97 Mil) to Dec. 2024 (zł11.67 Mil) and increased from Dec. 2024 (zł11.67 Mil) to Dec. 2025 (zł12.14 Mil).

Read-Gene Total Liabilities Related Terms

Read-Gene Total Liabilities Historical Data

* Premium members only.

The historical data trend for Read-Gene's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Read-Gene Total Liabilities Chart

Read-Gene Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Liabilities

Get a 7-Day Free Trial

9.98

10.14

10.97

11.67

12.14

Read-Gene Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Liabilities	Get a 7-Day Free Trial															10.52	12.92	10.53	12.14	10.24

80GF Score

Read-Gene SA WAR:RDG

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Read-Gene Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Read-Gene's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.999	+	(8.3	+	1.842
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	12.14

Total Liabilities	=	Total Assets (A: Dec. 2025 )	-	Total Equity (A: Dec. 2025 )
	=	15.254	-	3.112
	=	12.14

Read-Gene's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2.057	+	(0	+	8.185
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	10.24

Total Liabilities	=	Total Assets (Q: Mar. 2026 )	-	Total Equity (Q: Mar. 2026 )
	=	14.851	-	4.609
	=	10.24

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of zł10.24 Mil mean?

Read-Gene (WAR:RDG) has a Total Liabilities of zł10.24 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Read-Gene and its competitors.

Is Read-Gene's Total Liabilities too high?

Read-Gene's current Total Liabilities is zł10.24 Mil. Overall, Read-Gene has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Read-Gene's Total Liabilities compare to VRTX and REGN?

Read-Gene's Total Liabilities of zł10.24 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Biotechnology company?

A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Read-Gene and its competitors. Read-Gene's current Total Liabilities is zł10.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Read-Gene stock overvalued right now?

Based on GuruFocus' analysis, Read-Gene (WAR:RDG) is currently considered Modestly Undervalued. The stock's GF Value™ is zł6.37, compared to a current price of zł4.86 — trading 23.7% below its estimated fair value. The current Total Liabilities is zł10.24 Mil. Read-Gene's overall GF Score™ is 80/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For Read-Gene (WAR:RDG), the current Total Liabilities is zł10.24 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Read-Gene (WAR:RDG) Overvalued in 2026?

Based on GuruFocus' analysis, Read-Gene stock appears to be undervalued. The current stock price of zł4.86 is trading 23.7% below its estimated GF Value™ of zł6.37. GuruFocus considers Read-Gene to be Modestly Undervalued.

Key valuation signals for WAR:RDG:

Total Liabilities: zł10.24 Mil
GF Value™: zł6.37 vs. price of zł4.86 (23.7% below fair value)
GF Score™: 80/100 with 1 warning sign

No single metric tells the full story. See the WAR:RDG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Read-Gene Business Description

Industry Healthcare Biotechnology

Comparable Companies WAR:URT WAR:PHR WAR:PUR WAR:SCS WAR:GX1 WAR:NNG WAR:MAB WAR:PTG WAR:MOC WAR:SVE VRTX REGN XBRU:ARGX XBRU:UCB XKRX:207940 RVMD ASX:CSL ALNY ONC XKRX:068270

Address Ulica Alabastrowa 8, Grzepnica, Dobra, POL, 72-003

Website http://www.read-gene.com

Read-Gene SA treats each patient individually based on genetic tests. The company's segments include chemoprevention, clinical trials and genetic tests. It also engaged in developing technologies to commercialize methods to detect, prevent and treat malignant tumours.

80GF Score

Get the complete analysis for WAR:RDG

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł4.86

Price

zł6.37

GF Value

View WAR:RDG Analysis

See Total Liabilities data for all stocks →